New scan could spare thousands from unnecessary kidney surgery

NCT ID NCT06076538

Recruiting now Diagnosis Sponsor: University of Texas Southwestern Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 2 times

Summary

This study is testing whether a combined PET and MRI scan (PET/MR) can better tell apart aggressive kidney cancers from slow-growing or harmless tumors. About 97 adults with a suspicious kidney mass will receive the scan during their regular MRI appointment. Researchers hope this approach reduces unnecessary surgeries by improving how doctors identify which tumors truly need treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FDG (a radioactive tracer) and furosemide (a diuretic)
What this could lead to: If successful, this could lead to a more accurate imaging method to distinguish aggressive kidney cancers from slow-growing or benign tumors, helping avoid unnecessary treatments.
What could go wrong: This is an early observational study with only 97 participants, so results may not apply to everyone. The scan uses radiation and may not be widely available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

kidney benign neoplasm kidney neoplasm renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RENAL CELL CARCINOMA RENAL TUMOR RENAL TUMOR, BENIGN

Contacts and locations

Locations

The University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
University of Texas Southwestern Medical Center
RECRUITING

Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.